Retatrutide
Triple-receptor agonist in late-stage trials with ~24% mean weight loss at 48 weeks. Not yet approved.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Also: LY3437943
Triple-receptor agonist in late-stage trials with ~24% mean weight loss at 48 weeks. Not yet approved.
Evidence Intelligence Score™
- Preclinical
- Pilot human
- RCT← current
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data8.8
- Safety maturityFollow-up depth and adverse-event signal7.3
- Mechanism confidencePathway specificity and clarity6.0
- Clinical readinessDistance to physician-prescribable use7.8
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts4.4
- Long-term dataFollow-up beyond initial trial windows5.4
- Translational confidenceAnimal → human signal preservation7.6
Effects on the indexed outcomes are supported by randomized human data, with 1 citation on file.
Effect sizes outside trial populations and durations beyond the studied window remain less characterized.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: maturing. Expect the consensus to harden as multi-site replications publish.
Weight / fat reduction
1 study- strongJastreboff AM, Kaplan LM, Frias JP, et al.
-24.2% with retatrutide 12 mg/wk vs -2.1% placebo at 48 wk.
RCTn=3382023unreviewed
Cardiometabolic health
1 study- strongRosenstock J, Frias JP, Jastreboff AM, et al.
HbA1c -up to 2.16%; weight -up to 16.94% vs placebo at 36 wk.
RCTn=2812023unreviewed
Appetite & food-noise suppression
1 study- moderateJastreboff AM, Kaplan LM, Frias JP, et al.
Dose-dependent weight reductions over 48 wk consistent with sustained energy-intake reductions; dedicated ad-libitum study not yet published.
RCTn=3382023unreviewed
Weight / fat reduction
1 regimenMostly GI AEs; transient HR increases.
48-wk investigational protocol; not regulator-approved.
Cardiometabolic health
1 regimenDose-dependent GI AEs; small transient HR increase. Not approved.
36-wk investigational protocol in T2D on diet/exercise or metformin.
Appetite & food-noise suppression
1 regimenSee obesity Phase 2 profile.
No dedicated ad-libitum appetite RCT yet; regimen drawn from obesity Phase 2.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.
1 brand across three tiers.
Research-use only
1 brandSold by chemical suppliers labelled 'for laboratory research only — not for human consumption'. No pharmaceutical-grade QC, no medical oversight. Listed for transparency.